ArticleJournal of Cancer2017

Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.

Zhen Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.